Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics #Biotechnology #CSEStocks #Chemicals #DTC.C #DTC.CA #DTCFF #Investing #Medical #OTC #OTCMarkets #OTCStocks #Pharmaceutical #Pharmaceuticals #SmallCaps

Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various indications related to immune-oncology.Whether using an antibody, cell-based vaccine or small molecule therapeutics, the common denominator in all of Defence's development products...
http://dlvr.it/Svz4vx

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

ASTRA TT Signs Strategic MOU with India's BIS to Accelerate Green Charging Infrastructure Across the Nation #Publishing #Technology